HealthcareHealthcare ServicesHealthcare Service Provider

Transgene Biotek Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 37 filings·Updated 25 Sept 2026
Showing 10 of 37 filings.
25 Sept 20261 filing
Company UpdateGeneral

ROC extends Transgene Biotek's 36th AGM deadline by three months to December 31, 2026

AGM extension details

  • ROC Hyderabad granted a total extension of three months for the AGM.
  • The 36th AGM for FY2026 may be held on or before December 31, 2026.
Filed 11:53View Source
23 Sept 20261 filing
Company UpdateResignation of Statutory Auditors

Intimation of Resignation of Statutory Auditors-M/s. Vasavi & Co., Chartered Accountants (FRN:020965S).

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 19:46View Source
22 Sept 20261 filing
Insider Trading / SASTClosure of Trading Window

Transgene Biotek Ltd: Trading window closed from 01 October 2026 until completion of Forty Eight (48) hours after the declaration of Limited reviewed Financial Results of the Company for the second quarter to be ended on 30th September, 2026

Transgene Biotek Ltd: Trading window closed from 01 October 2026 until completion of Forty Eight (48) hours after the declaration of Limited reviewed Financial Results of the Company for the second quarter to be ended on 30th September, 2026

Filed 17:37View Source
11 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 12:52View Source
7 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Transgene Biotek Board approves Q1 2026-27 unaudited results, AGM extension, and internal auditors.

Key board decisions

  • Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
  • Limited Review Report (standalone & consolidated) for quarter ended 30 June 2026 approved.
  • AGM extension for FY2025-26 approved, subject to ROC approval.
  • Appointed M/s Manisha Dubey & Associates as Internal Auditors for FY2026-27.
  • Regulatory disclosure under Regulation 30: internal auditor appointment details provided.
  • Auditor note: consolidated quarterly results not reviewed.
  • SAT matter adjourned to 17 August 2026.
  • ED order hearing started; adjourned to 10 September 2026.
  • NCLT matter adjourned to 23 September 2026.
  • Nitin Didwania: order dated 8 July; appeal filed.
  • BIRAC: no communication since 14 November 2025.
  • Customs & Excise: no new development.
Filed 11:42View Source
13 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) certificate confirms dematerialisation processing, listing, and cancellation actions

Dematerialisation status

  • Dematerialisation requests processed; RTA confirmed accepted/rejected to depositories for the quarter.
  • Securities dematerialised have been listed on the stock exchange where earlier issues are listed.
  • Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within the prescribed timeline.
Filed 19:28View Source
29 May 20261 filing
Board MeetingOutcome of Board Meeting

Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2026

Financial results

  • Board approved audited standalone and consolidated results for Q4 and FY ended 31 March 2026.
  • Standalone and consolidated auditors issued unmodified opinions on the audited results.

Key performance

  • Standalone FY 2025-26 profit before tax was a loss of ₹165.29 lakh.
  • Consolidated FY 2025-26 profit before tax was a loss of ₹165.29 lakh.
  • Standalone and consolidated basic EPS for FY 2025-26 was negative ₹0.22 per share.

Other statements approved

  • Board approved audited standalone and consolidated cash flow statements for FY 2025-26.
  • Board approved standalone and consolidated balance sheets and related notes.

Regulatory and legal matters

  • Company disclosed ongoing appeals before SAT, ED Tribunal, and NCLT with future hearing dates.
  • Company reported no further development in customs and excise matters.
  • Company reported no further communication from BIRAC since 14 November 2025.
Filed 11:35View Source
15 May 20261 filing
Board Meeting

Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting Of The Company - This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Friday 29Th May 2026.

Meeting Details

  • Board meeting scheduled for Friday, 29 May 2026.

Key Agenda Items

  • Approve audited standalone and consolidated financial results for Q4 and year ended 31 March 2026.
Filed 09:25View Source
13 Apr 20262 filings
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 18:06View Source
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Non-Applicability of Regulation 32(1) of SEBI.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 18:01View Source
Showing 10 of 37 filings